UNSPSC 85714904: Revision of autologous tissue substitute in left temporomandibular joint, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to revision of autologous tissue substitute in left temporomandibular joint, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0RWD37Z

UNSPSC 85714904 Revision of autologous tissue substitute in left temporomandibular joint, percutaneous approach is a Commodity code that shows no relevant recent state and local procurement activity. The code's nominal scope—a surgical revision procedure for a specific joint using tissue substitutes—does not align with the recent opportunities posted under this code number. The solicitations tagged to this code are for independent medical evaluation services, surgical benefit carve-out programs, occupational medical surveillance, emergency and specialty healthcare for detained youth, pharmacy benefit management, and temporary health professional staffing. These opportunities reflect health service administration, benefits management, occupational health compliance, and clinical staffing—not orthopaedic or maxillofacial surgical procedures or tissue-substitute product procurement. The mismatch suggests either data-entry error in the tagging of opportunities to the UNSPSC code or a systemic divergence between the code's intent and how state and local issuing bodies are actually using it in practice.

The recent opportunities do span multiple issuing bodies—a city retirement office (Phoenix), municipal government (Long Beach), a state transportation agency (Washington), a county juvenile justice department (Harris County), a county board of commissioners (Collier County), and a county health system (Santa Clara)—across Arizona, California, Washington, Florida, and Texas. However, none of these opportunities involve the tissue-substitute revision procedure the code nominally describes, rendering this code unsuitable for business development planning in orthopaedic implants, surgical devices, or tissue-engineering product lines.